CytomX Therapeutics (CTMX) Price & Analysis

Compare

833 Followers

CTMX Stock Chart & Stats

$3.93

-$0.06(-5.83%)

At close: Jan 08 4:00 PM EST

$3.93

-$0.06(-5.83%)

Day’s Range― - ―

52-Week Range$0.40 - $4.16

Previous CloseN/A

Volume1.08M

Average Volume (3M)3.88M

Market Cap

$674.49M

Enterprise Value$141.80M

Total Cash (Recent Filing)$79.89M

Total Debt (Recent Filing)$8.15M

Price to Earnings (P/E)7.2

Beta2.79

Next Earnings

Nov 06, 2025

EPS Estimate

-0.05

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.00

Shares Outstanding164,912,900

10 Day Avg. Volume2,556,049

30 Day Avg. Volume3,878,630

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.21

Enterprise Value/Revenue0.96

Enterprise Value/Gross Profit0.96

Enterprise Value/Ebitda3.77

Forecast

1Y Price Target

$5.50

Price Target Upside39.95% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical EfficacyInitial CX-2051 data are tracking ahead of standard care product benchmarks, showing promising efficacy results.

Financial PerformanceCTMX reported no net loss or $0/share, above the estimate of ($0.14).

Safety ProfileNo dose-limiting toxicities or discontinuations were reported, which is a positive safety indicator.

Bears Say

Market ReactionThe market has already reacted to the development, with shares of CytomX down ~20% since the day prior to the press release.

Safety ConcernsThe company disclosed a grade 5 event of treatment-related acute kidney injury, which appears to be an isolated incident but still requires attention.

CytomX Therapeutics News

CytomX Therapeutics management to meet with Oppenheimer

Meeting to be held on October 23-24 hosted by Oppenheimer. Published first on TheFly – the ultimate source...

15d ago

CTMX

CytomX Therapeutics price target raised to $6 from $3.50 at Barclays

Barclays analyst Etzer Darout raised the firm’s price target on CytomX Therapeutics (CTMX) to $6 from $3.50 and...

15d ago

CTMX

CytomX Therapeutics appoints Rachael Lester as chief business officer

CytomX Therapeutics (CTMX) announced the appointment of Rachael Lester as senior VP, chief business officer. In this role,...

16d ago

CTMX

Oppenheimer positive on CytomX after Merus colon cancer data

Oppenheimer says Merus’ (MRUS) colon cancer data update reinforces its “enthusiasm” for CytomX Therapeutics’ (CTMX) dose expansion data....

22d ago

CTMX

MRUS

CytomX Therapeutics Advances CX-2051 Study in Solid Tumors

CytomX Therapeutics Inc. (($CTMX)) announced an update on their ongoing clinical study. Study Overview: CytomX Therapeutics Inc. is...

9d ago

CTMX

Cautious Hold Rating on CytomX Therapeutics Amid Safety Concerns and Awaited Phase 1 Data for CX-2051

J.P. Morgan analyst Anupam Rama has maintained their neutral stance on CTMX stock, giving a Hold rating on...

9d ago

CTMX

CytomX Therapeutics: Hold Rating Amid Awaited CX-801 Data and Market Potential

J.P. Morgan analyst Anupam Rama has maintained their neutral stance on CTMX stock, giving a Hold rating today....

1M ago

CTMX

CytomX Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of CytomX Therapeutics (CTMX) with an Overweight rating and $6 price target CytomX may...

1M ago

CTMX

CytomX Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of CytomX Therapeutics (CTMX) with an Overweight rating and $6 price target Published first...

1M ago

CTMX

CytomX Therapeutics assumed with an Overweight at Barclays

Barclays analyst Etzer Darout assumed coverage of CytomX Therapeutics (CTMX) with an Overweight rating and $3.50 price target...

2M ago

CTMX

CytomX Therapeutics initiated with an Overweight at Barclays

Barclays initiated coverage of CytomX Therapeutics (CTMX) with an Overweight rating and $3.50 price target Published first on...

2M ago

CTMX

Barclays sees ‘significant potential’ in CytomX’s CX-2051 despite safety event

After CytomX disclosed an update on its lead pipeline program, CX-2051, and shared information on patient enrollment and...

3M ago

CTMX

CytomX trial ongoing despite grade five event, says Oppenheimer

Oppenheimer says shares of CytomX Therapeutics (CTMX) fell 20% yesterday after a post on a patient forum that...

3M ago

CTMX

CytomX Therapeutics Updates on CX-2051 Phase 1 Study

The latest announcement is out from CytomX Therapeutics ( ($CTMX) ). On August 13, 2025, CytomX Therapeutics announced...

3M ago

CTMX

CTMX FAQ

What was CytomX Therapeutics Inc’s price range in the past 12 months?

CytomX Therapeutics Inc lowest stock price was $0.40 and its highest was $4.16 in the past 12 months.

What is CytomX Therapeutics Inc’s market cap?

CytomX Therapeutics Inc’s market cap is $674.49M.

When is CytomX Therapeutics Inc’s upcoming earnings report date?

CytomX Therapeutics Inc’s upcoming earnings report date is Nov 06, 2025 which is tomorrow.

How were CytomX Therapeutics Inc’s earnings last quarter?

CytomX Therapeutics Inc released its earnings results on Aug 07, 2025. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.063 by $0.063.

Is CytomX Therapeutics Inc overvalued?

According to Wall Street analysts CytomX Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does CytomX Therapeutics Inc pay dividends?

CytomX Therapeutics Inc does not currently pay dividends.

What is CytomX Therapeutics Inc’s EPS estimate?

CytomX Therapeutics Inc’s EPS estimate is -0.05.

How many shares outstanding does CytomX Therapeutics Inc have?

CytomX Therapeutics Inc has 164,912,900 shares outstanding.

What happened to CytomX Therapeutics Inc’s price movement after its last earnings report?

CytomX Therapeutics Inc reported an EPS of $0 in its last earnings report, beating expectations of -$0.063. Following the earnings report the stock price went up 11.905%.

Which hedge fund is a major shareholder of CytomX Therapeutics Inc?

Currently, no hedge funds are holding shares in CTMX

CytomX Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

108.21%

Trailing 12-Months

Asset Growth

9.95%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

CytomX Therapeutics Inc

CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on advancing a new class of cancer therapeutics known as Probody therapeutics. These innovative therapies are designed to selectively target tumors while sparing healthy tissue, thereby potentially reducing side effects associated with traditional cancer treatments. The company operates primarily within the oncology sector and is developing a pipeline of proprietary and partnered therapeutics that leverage its Probody platform to enhance the efficacy and safety of existing cancer therapies.

CytomX Therapeutics (CTMX) Earnings & Revenues

Historic Earnings Reports

CTMX Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted significant clinical progress, particularly with CX-2051, and strong financial positioning, although there were challenges with decreased revenue and common adverse events in clinical trials.View all CTMX earnings summaries

CTMX Stock 12 Month Forecast

Average Price Target

$5.50

▲(39.95% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","-1":"-$1","1.25":"$1.25","3.5":"$3.5","5.75":"$5.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.25,3.5,5.75,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.57,3.833846153846154,4.0976923076923075,4.361538461538461,4.625384615384615,4.889230769230769,5.153076923076923,5.4169230769230765,5.680769230769231,5.944615384615384,6.208461538461538,6.472307692307693,6.7361538461538455,{"y":7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.57,3.7184615384615385,3.8669230769230767,4.015384615384615,4.163846153846154,4.312307692307693,4.46076923076923,4.609230769230769,4.757692307692308,4.906153846153846,5.054615384615385,5.203076923076923,5.351538461538461,{"y":5.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.57,3.5646153846153843,3.559230769230769,3.5538461538461537,3.5484615384615386,3.543076923076923,3.5376923076923075,3.5323076923076924,3.526923076923077,3.5215384615384613,3.516153846153846,3.5107692307692306,3.5053846153846155,{"y":3.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.18,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.05,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.09,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.03,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.68,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.58,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.76,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.51,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.36,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.35,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.08,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.35,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.57,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >